Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced the release of a new review paper titled “Immunohistochemistry in Prostate Pathology” that illustrates the significant impact immunohistochemistry (IHC) can have on diagnostic prostate pathology.
The paper is co-authored by two leading global experts in prostate pathology: Glen Kristiansen, M.D., professor at the Institute of Pathology, University Hospital of Bonn, Germany, and Jonathan I. Epstein, M.D., professor at the departments of Pathology, Urology and Oncology at the Johns Hopkins Hospital Medical Institutions in Baltimore, Md. The review concisely illustrates how IHC can contribute substantially to diagnostic prostate pathology if used with care and experience.
The paper offers prostate pathologists a comprehensive reference that discusses the use of various prostate markers, as well as their limitations, and is intended to be a helpful companion for pathologists in their daily work. “This is one of the most concise and up-to-date collections of the cornerstones, pearls and pitfalls of immunohistochemistry in prostate diagnostics,” said Kristiansen. “It will give the clinical pathologist a quick overview over this exciting field that has evolved so rapidly in the last decade.”
Kristiansen’s co-author concurred. “‘Immunohistochemistry in Prostate Pathology’ in one source comprehensively covers both commonly used and lesser known but very useful antibodies for the diagnosis of prostate cancer, along with pitfalls in their use,” said Epstein.
The prevalence of prostate cancer is growing, with an estimated 1.1 million men worldwide diagnosed in 2012. Prostate cancer currently accounts for 15 percent of the cancers diagnosed in men, and it is predicted that the number of cases will almost double to 1.7 million by 2030. (1, 2)
“We were very pleased to collaborate with renowned experts like Dr. Kristiansen and Dr. Epstein,” said Britt Meelby Jensen, Dako general manager and Agilent vice president. “Providing pathologists with an unmatched comprehensive and high-quality portfolio is a priority for Dako in our relentless fight against cancer.”
Dako offers exclusive IVD clones for two of the markers highlighted in the paper-AMACR (Clone 13H4) and Prostein (Clone 10E3).
About Dako – An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako became part of Agilent Technologies in 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
# # #
1 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 4/February/2014.
2 World Cancer Research Fund International (website) http://www.wcrf.org/cancer_statistics/data_specific_cancers/prostate_cancer_statistics.php